Arcturus Therapeutics

Arcturus therapeutics is a leading clinical-stage messenger RNA medicines company focused on the discovery, development and commercialization of therapeutics for rare diseases and vaccines. We have proprietary technologies, validating partnerships, and an experienced team with deep expertise in delivery and RNA-based therapeutics

Placeholder

Arcturus Therapeutics

  • Arcturus Therapeutics and Duke-NUS Medical School Partner to Develop a Coronavirus (COVID-19) Vaccine using STARR™ TechnologyREAD MORE
  • Arcturus Therapeutics Expands Platform with STARR™ TechnologyREAD MORE
  • Arcturus Therapeutics Receives up to $15 Million Commitment from the Cystic Fibrosis FoundationREAD MORE
  • Ultragenyx and Arcturus Therapeutics Expand Existing Research Collaboration and License AgreementREAD MORE
  • Synthetic GenomicsArcturus Therapeutics Announces Strategic Alliance with Synthetic Genomics, Inc. to develop self-amplifying RNA-based vaccines and therapeuticsREAD MORE

LUNAR®-mediated delivery of RNA into cells

LUNAR particles associate with the cell membrane of a target cell of interest and quickly enter the cell via endocytosis.

Upon entering the cytosol, the LUNAR formulations then become trapped in the endosomes.

With increased acidity as the endosome ages, a pH-mediated disruption enables release of the RNA payload following rapid biodegradation of the LUNAR components.

Once release of the RNA into the cytosol occurs, the translational machinery can interact with the RNA and processing and/or trafficking can then take place to make functional protein.

LUNAR® lipid mediated delivery enables delivery of RNA medicines.

News & Events

  • July 1, 2020

    Arcturus Therapeutics Announces the Formation of its Vaccine Platform Scientific Advisory Board

    • July 1 2020
    • 0
    read more
  • June 29, 2020

    Arcturus Therapeutics to be Added to Russell 2000® Index

    • June 29 2020
    • 0
    read more
  • June 11, 2020

    Arcturus Therapeutics to Present at the Raymond James Human Health Innovation Virtual Conference

    • June 11 2020
    • 0
    read more
  • June 5, 2020

    Arcturus Therapeutics Announces First Healthy Volunteer Dosed in Phase 1 Study of ARCT-810 for Ornithine Transcarbamylase (OTC) Deficiency

    • June 5 2020
    • 0
    read more
  • May 21, 2020

    Ultragenyx Announces Exercise of Option to Purchase Additional Stock of Arcturus Therapeutics

    • May 21 2020
    • 0
    read more
  • May 8, 2020

    Arcturus Reports Additional Supportive Preclinical Data for its COVID-19 Vaccine Candidate (LUNAR-COV19)

    • May 8 2020
    • 0
    read more
  • May 7, 2020

    Arcturus Therapeutics Announces First Quarter 2020 Financial Results and Provides a Corporate Update

    • May 7 2020
    • 0
    read more
  • May 5, 2020

    Arcturus Therapeutics to Report First Quarter 2020 Financial Results and Provide a Corporate Update on May 7, 2020

    • May 5 2020
    • 0
    read more
  • May 4, 2020

    Arcturus Therapeutics and Catalent Announce Partnership to Manufacture mRNA-Based COVID-19 Vaccine

    • May 4 2020
    • 0
    read more